Skip to main content
OpenTrials
Completed

NCT Number: NCT00859872

Efficacy and Safety of Risperidone Oral Solution Combination Clonazepam Versus Haloperidol Intramuscular (IM) Injection for Treatment of Acute Psychotic Agitation in Schizophrenia

This is a multi-centre, open, randomized, haloperidol-referenced, 47 days two treatment sessions, parallel-group study.

After screening period, eligible subjects will be entered 5 days treatment session I to compare the efficacy between risperidone oral solution combination clonazepam oral and haloperidol IM injection on controlling psychotic agitation, then will be followed by 6 additional weeks treatment session II for exploring the effect of medicine switching from IM injection to oral.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

MentalHealth Institute of the 2nd Xiangya Hospital, Central South University

Changsha, Hunan, 410011, China

About this study

Acute psychotic agitation is a common problem in many patients with schizophrenia that includes agitation, aggression, excitement and violence. An investigation showed that about 26% psychotic patients were brought to the psychiatric emergency room because of the psychotic agitation symptoms. The primary objective is to compare the efficacy between risperidone oral solution combination clonazepam oral and haloperidol IM injection on controlling psychotic agitation in patients of acute schizophrenia and schizophrenic-affective disorder.

The secondary objectives are: (1) to explore the possibility of decreasing efficacy of acute 6 weeks treatment from IM injection to oral; (2) to compare the safety between risperidone oral solution combination clonazepam oral and haloperidol IM injection.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Men or women aged 18 to 45 years
  • DSM-IV diagnosis of acute exacerbation of schizophrenia or schizoaffective disorders
  • A score of ≥ 14 on a 5-item acute-agitation cluster (including excitement, hostility, uncooperativeness and poor impulse control) derived from the PNASS
  • The total scores ≥60 on the PANSS

Exclusion criteria

  • Women who are pregnant or breast feeding, or who plan to become pregnant during the study
  • The psychotic agitation is caused by delirium, epilepsy, mental retardation and affective disorder; intoxication or symptoms of withdrawal from alcohol or other psychoactive substances
  • Clinical laboratory values indicating serious medical illness
  • Known hypersensitivity to any of the study medications
  • Treatment with a depot antipsychotic with 1 cycle of screening
  • Using of disallowed medication

Treatment and study plan

Risperidone oral solution

Drug

risperidone oral solution (2-6mg/d) combination clonazepam (4-8mg/d) oral

Haloperidol

Drug

haloperidol IM injection (5-20mg/d)

Primary outcomes

  1. the change of PANSS-EC scores

    Time frame: 5 days

Secondary outcomes

  1. response rate based on the PANSS

    Time frame: 47 days

Sponsors and collaborators

Lead sponsor

Central South University

Other

Collaborators

  • Capital Medical University
  • Chongqing Mental Hospital
  • Guangzhou Mental Hospital
  • Shanghai Mental Health Center
  • Wuhan Mental Health Centre

Registry information

Official study title

Efficacy and Safety of Risperidone Oral Solution Combination Clonazepam Versus Haloperidol IM Injection for Treatment of Acute Psychotic Agitation in Schizophrenia

Important dates

Study start
2008
Primary completion
2009
Study completion
2009
First posted
Mar 11, 2009
Registry last updated
Aug 3, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.